Potency assay development uses DoE and QbD to improve accuracy, consistency, and regulatory readiness in biologics testing.

An ELRIG webinar has explored how cell-based screening supports drug discovery, from early target validation to advanced ...

OTC deficiency is a rare genetic condition and the most prevalent urea cycle disorder. Newborns with neonatal onset OTC deficiency exhibit hyperammonemia symptoms shortly after birth, including ...

When we hear that a person has quirks, we expect to be charmed. But when we hear that a cell-based assay has quirks, we expect to be frustrated. Quirks in cell-based assays tend to complicate drug ...

Avance Biosciences opened its new Potency and Cell-Based Assay Center of Excellence, a purpose-built facility designed to expand and centralize the company’s capabilities in potency and functional ...

A new Armatus publication summarizes a novel potency assay platform to advance gene silencing therapies for rare neuromuscular diseases.

Funding supports expansion of manufacturing and commercial capacity for SemaCyte microcarrier platform Semarion, a University of Cambridge spin-out company from the Cavendish Laboratory combining ...

In the ever-evolving landscape of biomedical research, the need for reliable, consistent, and ready-to-use cell models has never been more critical. ATCC, a leading provider of biological materials, ...

Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell analysis and isolation, today announced the launch of Cyto-Cellect® Fc Fusion, a novel assay designed to ...

BURLINGAME, CA, UNITED STATES, February 16, 2026 /EINPresswire.com/ -- The Global Business Landscape is being reshaped by rapid innovation, rising investment and ...